<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204534">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000442</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAKRA3510</org_study_id>
    <secondary_id>P50AA003510</secondary_id>
    <nct_id>NCT00000442</nct_id>
  </id_info>
  <brief_title>Naltrexone for Relapse Prevention</brief_title>
  <official_title>Etiology and Treatment of Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Connecticut Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Connecticut Health Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and effectiveness of an injectable slow releasing
      preparation of naltrexone to reduce alcohol consumption and risk of relapse in
      alcohol-dependent subjects. Individuals will receive either naltrexone or a placebo
      injection for a total of three months, with two subsequent followup visits spanning a 6-
      month period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date>December 2002</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment</study_design>
  <enrollment>57</enrollment>
  <condition>Alcoholism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone (Revia)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets criteria for alcohol dependence.

          -  Abstinent from alcohol for a period of at least 3 days prior to beginning of study.

          -  Able to read English and complete study evaluations.

          -  Females who are postmenopausal, have had surgical sterilization, or use reliable
             means of birth control.

        Exclusion Criteria:

          -  Meets criteria for dependence on a psychoactive substance other than alcohol and
             nicotine and/or cannabis.

          -  Prior history of opioid dependence.

          -  Regular use of psychoactive drugs including anxiolytics and antidepressants.

          -  Prior treatment with naltrexone.

          -  Current use of disulfiram.

          -  Psychotic or otherwise severely psychiatrically disabled (e.g., suicidal, current
             mania).

          -  Significant underlying medical conditions such as hepatic, cerebral, renal, thyroid,
             or cardiac disease.

          -  Abstinent longer than 28 days prior to randomization.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 17, 2011</lastchanged_date>
  <firstreceived_date>November 2, 1999</firstreceived_date>
  <responsible_party>
    <name_title>Henry Kranzler</name_title>
    <organization>University of Pennsylvania</organization>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
